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In a previous report (Young et al., Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5802–5806), we
provided a proof-of-principle for fold recognition of proteins using a homobifunctional
amine-specific chemical crosslinking reagent in combination with mass spectrometry analysis
and homology modeling. In this current work, we propose a systematic nomenclature to
describe the types of peptides that are generated after proteolysis of crosslinked proteins, their
fragmentation by tandem mass spectrometry, and an automated algorithm for MS/MS
spectral assignment called “MS2Assign.” Several examples are provided from crosslinked
peptides and proteins including HIV-integrase, cytochrome c, ribonuclease A, myoglobin,
cytidine 5-monophosphate N-acetylneuraminic acid synthetase, and the peptide thymopen-
tin. Tandem mass spectra were obtained from various crosslinked peptides using post source
decay MALDI-TOF and collision induced dissociation on a quadrupole-TOF instrument, along
with their automated interpretation using MS2Assign. A variety of possible outcomes are
described and categorized according to the number of modified lysines and/or peptide chains
involved, as well as the presence of singly modified (dead-end) lysine residues. In addition, the
proteolysis and chromatographic conditions necessary for optimized crosslinked peptide
recovery are presented. (J Am Soc Mass Spectrom 2003, 14, 834–850) © 2003 American
Society for Mass Spectrometry
Recently we proposed a general method, massspectrometry for 3 dimensional analysis (MS3D)for determination of the fold family of a protein
based on the combined use of chemical crosslinking,
mass spectrometry and computational modeling [1]. In
this proof-of-principle study, the homobifunctional
amine-specific reagent, bis(sulfosuccinimidyl)suberate
(BS3), was used to generate a set of intra- and inter-
molecular crosslinked proteins. After crosslinking, the
monomeric and oligomeric forms of these proteins were
then separated by size exclusion chromatography (SEC)
to discriminate between crosslinks occurring between
proteins (interprotein crosslinks) and ones formed be-
tween amino acids of the same protein monomer (in-
tramolecular crosslinks). While both types of crosslinks
are potentially of use, see for example Muller et al. [2],
our goal in the initial study was to identify intraprotein
crosslinks within the monomeric crosslinked protein
fraction to be used to generate a set of distance con-
straints for fold-family recognition. To provide this data
set, recombinant FGF-2 was crosslinked with BS3 and
the monomer fraction obtained after SEC separation
was subjected to proteolysis, HPLC separation and
mass spectrometric analysis. The mass spectrometric
analysis consisted of two steps: (1) An assignment of a
crosslinks based on mass only and, in some cases, (2)
confirmation of this preliminary assignment based on
tandem mass spectrometry. These two steps were ac-
complished primarily by MALDI-MS and MALDI-PSD,
respectively.
Since the publication of the FGF-2 study [1], we and
other groups have employed similar or more efficient
MS/MS techniques such as electrospray ionization
(ESI) on either a quadrupole-o-TOF or an ion-trap mass
spectrometer to better analyze the products of
crosslinking reactions. For example, Muller et al. [2]
reported crosslinks between Op18 and tubulin formed
in the native heterodimer using both MALDI-MS and
Published online June 25, 2003
Address reprint requests to Dr. B. W. Gibson, Buck Institute for Age
Research, 8001 Redwood Blvd., Novato, CA 94945, USA. E-mail:
bgibson@buckinstitute.org
*Also at the Department of Pharmaceutical Chemistry, University of
California, San Francisco, CA 94143-0446.
© 2003 American Society for Mass Spectrometry. Published by Elsevier Inc. Received February 24, 2003
1044-0305/03/$30.00 Revised April 10, 2003
doi:10.1016/S1044-0305(03)00327-1 Accepted April 11, 2003
nanoelectrospray tandem mass spectrometry on a Q-
TOF instrument. Similarly, the multimeric nuclear pore
complex Nup85p has been described using chemical
crosslinking and MALDI-MS analysis [3]. Wang and
colleagues have employed the use of fluorogenic
crosslinkers followed by MALDI-MS [4] and, more
recently, ESI-MS/MS analysis [5] to study the protein
interfaces in the nebulin-calmodulin complex, although
they also reported observing intra-molecular crosslinks.
In this latter respect, it is worth noting that we and
another group have recently described a method to
identify and distinguish between crosslinked peptides
that arise from intermolecular versus intramolecular
interactions in homodimers using a combination of
15N-labeled and unlabeled (14N) proteins [6, 7]. In an
effort to systematically investigate the conditions
needed for more efficient intermolecular crosslinking,
Pearson and colleagues [8] used several different
amine-specific crosslinking reagents on known pro-
teins, including cytochrome c and ribonuclease A. In
that study, both MALDI-MS and on-line HPLC-MS/MS
using both an ion-trap and Q-TOF mass spectrometer
were employed to analyze these complex peptide mix-
tures and to identify lower abundance crosslinking
events [8]. Similarly, Chen et al. [9] used an ion-trap
instrument to assign crosslinks between subunits of
human hemoglobin. Taking a somewhat different ap-
proach, Back et al. [10] have proposed the use of the
relatively short bifunctional lysine reactive crosslinkers,
N-benzyliminodiacetoylhydroxysuccinimid (BID) and
its water-soluble sulfated analog sulfoBID [11], for
protein crosslinking. These latter reagents contain a
marker that can be used for identifying crosslinked
peptides under MS/MS conditions and were success-
fully employed to identify and screen for crosslinked
peptides, including those originating from the yeast
mitochondrial prohibitin complex. Lastly, Trester-
Zedlitz and colleagues [12] at Rockefeller University
have recently proposed a novel modular solid-phase
synthesis strategy for crosslinking reagents based on a
peptide motif that also incorporates a biotin pulldown
label and isotopic tag. Both MALDI-MS and HPLC-
MS/MS was employed in their analysis of the
crosslinked heterodomeric protein complex negative
cofactor 2 (NC2) to define inter-molecular interactions
that also included a comprehensive computational anal-
ysis.
One clear advantage that MS/MS brings to crosslink-
ing studies is the higher degree of confidence in the
assignments as well as the potential to identify the
precise sites within the peptide chains that are modified
or crosslinked. However, given that several groups
have now published data demonstrating the utility of
using tandem mass spectrometry to identify chemically
crosslinked peptides, a need exists for a consistent and
unambiguous nomenclature to better describe their
spectra. This need is particularly critical in light of the
inherent complexity of low-energy tandem spectra that
must now consider more than one peptide chain in the
fragmentation process and the inadequate and confus-
ing nomenclature that has been employed in the vari-
ous reports. In addition, it would be highly desirable to
have automated software for identifying and describing
the peptide types and fragmentation processes they
undergo.
To address the issue of the proper assignment of
crosslinked peptides and to develop a more consistent
nomenclature for their description, we have analyzed
MS/MS spectra obtained from crosslinked peptides
derived from a variety of protein crosslinking experi-
ments and provided an interpretation of their fragmen-
tation mechanisms in a more rigorous fashion. Specifi-
cally, nomenclatures are presented that categorize the
different types of crosslinked peptides that are gener-
ated after crosslinking and proteolysis, as well as the
MS/MS fragmentation patterns that are obtained. To
automate the latter process, a program called
MS2Assign was developed that searches fragment
masses in tandem spectra and automatically assigns
these product ions according to the predicted peptide
chain sequences and cleavage sites. Both single and
multiple cleavage reactions are considered in the as-
signment and are based on the original Roepstorff
nomenclature [13] as modified by Biemann [14]. Lastly,
we discuss the importance of proteolysis and chromato-
graphic separation techniques to optimize the experi-
mental conditions for identification of crosslinked pep-




The proteins myoglobin (bovine skeletal muscle) and
cytochrome c (bovine heart) were purchased from
Sigma (St. Louis, MO), and ribonuclease A (bovine
pancreas) was purchased from Calbiochem (San Diego,
CA). The model peptide thymopentin was obtained
from Sigma (St. Louis, MO). The amine-specific homo-
bifunctional cross-linking reagent bis(sulfosuccinimi-
dyl)suberate (BS3) was obtained from Pierce (Rockford,
IL). Other cross-linking reagents used in these studies
included the bis(sulfosuccinimidyl) esters of de-
canedioic and dodecanedioic acids and were a gift from
Professor R. K. Guy at UCSF (manuscript in prepara-
tion). All materials were used without further purifica-
tion. Isotopically enriched N-15 media (Bio-Express cell
growth media, U 15-N) used to grow E. coli in protein
expression experiments was purchased from Cam-
bridge Isotope Laboratories (Andover, MA). For prote-
olysis of crosslinked proteins, sequencing grade, mod-
ified trypsin (porcine) was purchased from Promega
(Madison, WI) and sequencing grade endoproteinase
Glu-C and chymotrypsin (from bovine pancreas) were
purchased from Roche Molecular Biochemicals (India-
napolis, IN). The agarose-immobilized proteases TPCK
trypsin (bovine pancreas), V-8 Protease (Staphylococcus
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aureus) and chymotrypsin (bovine pancreas) were pur-
chased from Pierce (Rockford, IL). HPLC solvents such
as acetonitrile and water were obtained from Burdick
and Jackson (Muskegon, MI). The matrices used for
MALDI-MS experiments, i.e., -cyano-4-hydroxycin-
namic acid and sinapinic acid (3,5-dimethoxy-4-hy-
droxy-cinnamic acid) were purchased from Agilent
Technologies (Palo Alto, CA) and Aldrich (Milwaukee,
WI), respectively.
Preparation of Cytidine 5-Monophosphate
N-Acetylneuraminic Acid Synthetase
Cytidine 5-monophosphate N-acetylneuraminic acid
synthetase (CMP-NeuAc synthetase) from Haemophilus
ducreyi was expressed in E. coli BL21 (DE3) harboring
the pET24 expression construct containing the enzyme
(designated pET24CMP-NANA) in LB broth and puri-
fied according to Tullius et al. [15]. The 15[N]-labeled
CMP-NeuAc synthetase was prepared from the same E.
coli strain listed above but cultured in stable isotope
media (Bio-Express cell growth media, U 15-N). Based
on the observed mass shift and isotopic abundance
profile of several tryptic peptides isolated from 15[N]-
labeled CMP-NeuAc synthetase, an efficiency of 98%
was determined for the incorporation of N-15.
Peptide and Protein Crosslinking and Proteolysis
The amine-specific homobifunctional crosslinker BS3
(Pierce) was used to crosslink lysine residues in myo-
globin, cytochrome c, ribonuclease A, and CMP-NeuAc
synthetase according to the following protocol: Proteins
were dissolved in PBS reaction buffer (20 mM
Na2HPO4, 0.15 M NaCl) at pH 7.6 and dialyzed over-
night at 4 °C against 20 mM PBS reaction buffer using
Slide-A-Lyzer10K dialysis cassettes (Pierce; Rockford,
IL) to a final protein concentration of 10 M. To these
protein solutions, a 20- or 50-molar excess of freshly
prepared crosslinking reagents (BS3 or the bis(sulfosuc-
cimidyl) esters of decanedioic or dodecanedioic acid)
was added and incubated for 4 h at 4 °C. Thymopentin
(Arg-Lys-Asp-Val-Tyr) was crosslinked by dissolving
the peptide in PBS buffer (15 mM Na2HPO4, 0.65 M
NaCl, 1 mM EDTA, 3 mM DTT) at pH 7.3 to a
concentration of 0.67 mM and adding freshly prepared
BS3 to a final concentration of 4 mM followed by
incubation for 30 min at room temperature.
Crosslinked proteins were subjected to thorough
denaturation using procedures recently reviewed by
Medzihradszky [16] prior to proteolytic digestion. Typ-
ically, proteins were incubated at 60 °C for 1 h either in
a solution of 10 mM DTT and 6 M guanidine hydro-
chloride (GuHCl), or in a solution of 10 mM DTT and
40% acetonitrile (ACN). Cysteine-containing proteins
were then alkylated with 50 mM iodoacetamide (37 °C,
1 h). Prior to proteolytic digestion, the reaction mixtures
were diluted 1:4 to provide conditions that were com-
patible with the proteases that were subsequently em-
ployed. A panel of proteases consisting of trypsin,
endoproteinase Glu-C, and chymotrypsin, were used
either alone or in combination to produce a thoroughly
digested protein as judged by MALDI-MS profiling of
the reaction products. Typically an enzyme/protein
ratio of 1:20 (wt/wt) was sufficient for complete diges-
tion when incubated overnight (16 h). These proteases
were used either in their free or immobilized forms.
Mass Spectrometry and Chromatography
Mass spectra of peptides and proteins were obtained by
MALDI-MS on a Voyager DESTR plus time-of-flight
(TOF) mass spectrometer (Applied Biosystems, Fra-
mingham, MA) operating in the positive-ion mode
(reflectron mode for peptides and linear mode for
proteins). The instrument was equipped with a nitrogen
laser and operated under delayed extraction conditions
[17]; delay time was 190 ns for peptides (reflectron
mode) and 750 ns for proteins (linear mode), grid
voltage was 66–70% (reflectron mode) and 93% (linear
mode), respectively, of full acceleration voltage (20–25
kV). Samples were purified and fractionated by re-
versed-phase Zip TipsC18 (C-18 resin) or Zip TipsC4 (C-4
resin) (Millipore, Bedford, MA) by eluting the peptides
in a stepwise process, i.e., 10, 20, 40, and then 60% ACN
for C-4 resin-containing Zip Tips. All peptide samples
were prepared using a matrix solution consisting of 33
mM -cyano-4-hydroxycinnamic acid in acetonitrile/
methanol (1/1; vol/vol); 1 L of analyte (0.1–1 pmol of
material) was mixed with 1 L of matrix solution and
air-dried at room temperature on a stainless steel target.
Typically, 50 laser shots were used to record each
spectrum. Mass spectra were externally calibrated with
an equimolar mixture of angiotensin I, ACTH 1-17,
ACTH 18-39, and ACTH 7-38. For better mass accuracy,
most MALDI spectra were also internally calibrated
using expected proteolytic fragments of the target pro-
teins that had not undergone crosslinking. To confirm
the identity of peptides, mass spectra were also run
under post-source decay conditions (PSD) [18]. Proteins
were analyzed in the linear mode directly after chemical
crosslinking to determine the amount of reacted
crosslinking reagent per protein. A saturated solution of
sinapinic acid (3,5 dimethoxy-4-hydroxycinnamic acid)
in ACN/H2O/TFA (50:49:1) was used as matrix for
protein. Commercially available cytochrome c and
myoglobin were used as external calibrants.
The peptide mixtures obtained after proteolysis of
the crosslinked proteins were further analyzed by re-
versed-phase HPLC connected to a quadrupole orthog-
onal TOF mass spectrometer (QSTAR Pulsar i, MDS
Sciex, Canada). The peptides containing both unmodi-
fied, modified and crosslinked peptides were separated
using an LC Packings Ultimate binary gradient nano-
HPLC system fitted with a Famos micro autosampler
and a Switchos micro column switching module (Di-
onex, Sunnyvale, CA). In most cases, an analytical C4
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nano-column (75 m i.d.  15 cm, Vydac, Hesperia,
CA) was used in combination with a Micro precolumn
C4 cartridge (300 m i.d.  5 mm, LC Packings). In
other cases, an analytical PepMap C18 nanocapillary
column (75 m i.d.  15 cm) was employed for on-line
peptide separation in combination with a Micro guard
column (C18-PepMap precolumn, 300 m i.d.  1 mm)
purchased from LC Packings. The peptides were first
loaded onto a C4 (or C18) guard-column and washed
with the loading solvent (H2O/0.05% TFA, 20 l/min)
for 5–10 min to remove salts and denaturing reagent.
Peptides were then transferred onto the analytical C4
(or C18) nanocapillary HPLC column and eluted at a
flow rate of 300 nl/min using the following gradient:
2% B for 0–5 min, 2–70% B for 5–55 min, followed by
70% B for 55–65 min. Solvent A consisted of 0.05%
formic acid in 98% H2O/2% ACN and solvent B con-
sisted of 0.05% formic acid in 98% ACN/2% H2O. A
Protana nanospray ion source operating with a needle
voltage 2300 V was used to couple the eluant from the
nanocapillary columns to the QSTAR. Mass spectra
(ESI-MS) and tandem mass spectra (ESI-MS/MS) were
recorded in positive-ion mode with a resolution of
12,000–15,000 FWHM and collection times of 1 and
3 seconds, respectively. For collision-induced-dissocia-
tion tandem mass spectrometry (CID-MS/MS), the
mass window for precursor ion selection of the quad-
rupole mass analyzer was generally set to 1 m/z. The
selected ions were fragmented in a collision cell using
nitrogen as the collision gas and analyzed in the orthog-
onal TOF. A “rolling collision energy” was selected for
each precursor ion (25–50 eV) that is dependent on its
charge state and m/z value according to the following
equation; collision energy (eV)  (0.0625  m/z) 
intercept, where the intercept was 3, 5, and 6 for z
 2, 3, and 4, respectively. The LC-MS runs on the
QSTAR instrument were acquired in so called advanced
“Information Dependent Acquisition” mode (advanced
IDA), which allows the user to acquire MS/MS data in
an automated controlled fashion during the course of
an LC gradient. The survey MS scan is rapidly pro-
cessed and subsequently MS/MS candidates are then
selected based on specific criteria, such as abundance, a
specific isotope pattern or an inclusion list of peptides.
Spectra were calibrated (in static nanospray) using
MS/MS fragment-ions of a renin peptide standard
(histidine immonium-ion at m/z 110.0713, and the b8-ion
fragment ion at m/z 1028.5312) providing a mass accu-
racy of 50 ppm.
Automated Peptide Assignments (ASAP
and MS2Assign)
The Automated Spectrum Assignment Program
(ASAP), developed at the University of California, San
Francisco [1] was used to suggest possible structures for
both crosslinked and non-crosslinked peptides result-
ing from the proteolytic digestion of crosslinked pro-
teins. Datasets of mass spectra obtained from
MALDI-MS and/or ESI-MS experiments were searched
with ASAP using a mass error of 50–100 ppm. Once a
crosslinked and/or modified peptide ion was assigned
with ASAP, we analyzed its MS/MS fragmentation
spectrum using MS2Assign, a program developed spe-
cifically for this current work to assign tandem mass
spectra of unmodified, labeled and/or crosslinked pep-
tides.
The input to MS2Assign consists of the peptide
amino acid sequence(s), the sites of crosslinking and/or
modification for each input peptide, the mass shifts due
to the crosslinking and/or modification reagents, a text
file containing a list of singly-charged product ion
peaks to assign, the mass type (monoisotopic or aver-
age), and the error threshold (ppm or Daltons) to use in
making assignments. With this information, MS2Assign
generates a theoretical library containing all of the
possible fragmentation products and assigns the prod-
uct ion list. The theoretical library is constructed based
on common peptide fragmentation pathways that result
in a,b,c-type, x,y,z-type, internal and immonium ions
with associated common losses of H2O, NH3, CO, and
CO2. In addition, MS2Assign calculates all of the frag-
ments generated from a list of user-defined peptide
mass modifications (for example, carbamidomethylated
cysteines) and/or a defined intra- or inter-peptide
crosslink. The number and type of user-defined modi-
fications used in the library calculation is completely up
to the user’s discretion. The current version of
MS2Assign only supports one crosslink per peptide or
pair of peptides, and does not calculate the fragmenta-
tion products generated from cleavages within the
crosslinker itself. The additional fragments due to user-
defined modifications or crosslinks are stored in the
theoretical library.
MS2Assign then attempts to assign each product ion
peak obtained in a MS/MS experiment from a given
protonated molecular ion (MH) to a species in the
fragmentation library to within a user-defined error
threshold (usually 50–100 ppm). The MS2Assign out-
put consists of a list of assigned peaks, with information
about the observed and theoretical masses, the experi-
mental error, the ion-type name, and sequence informa-
tion for each assigned species. MS2Assign summarizes
the number of successfully assigned peaks at the end of
the assignment calculation. For peaks with multiple
possible assignments within the given error range, all
assignments are listed in the output.
MS2Assign is a C program that is currently compiled
under IRIX, Linux and Windows. Assignment calcula-
tions for a typical set of crosslinked peptides take on the
order of seconds to perform, but the runtime of the
program scales linearly with the length of the input mass
list. Web-based versions of MS2Assign and ASAP are
available for beta testing at http://roswell.ca.sandia.gov/
mmyoung.
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Results and Discussion
General Strategy
As shown in Figure 1, a generic crosslinking experiment
designed to provide intramolecular distance constraints
can be described as consisting of seven to eight separate
steps. In Step 1, a dilute protein solution is prepared
and reacted with a specified crosslinking reagent. The
crosslinking reagent can be of several types, such as a
homo- or hetero- bifunctional crosslinker, that targets
one or more functional groups. Maintaining a dilute
protein concentration (e.g., low M) during the
crosslinking reaction is generally desirable in that it
helps to minimize or eliminate protein-protein interac-
tions that might favor crosslinking of amino acids
between proteins (i.e., interprotein crosslinking). If in-
terprotein crosslinking is a likely possibility under the
reaction conditions, separation of monomers from
dimers and other crosslinked oligomers should be car-
ried out, such as through SEC separation (optional Step
2). Such a separation step may be a sensible precaution
in all crosslinking experiments to avoid ambiguous
assignments and inferences. In Step 3, the crosslinked
protein is denatured and proteolyzed to produce a set
of crosslinked and non-crosslinked peptides. In Step 4,
the resulting peptide mixture is separated and charac-
terized by LC-MS. However, the desired crosslinked
peptides are generally of low relative molar abundance
and require careful and thorough examination of the
MS data to assign possible crosslinks. In our case, Step
5 is carried out using the Automatic Structure Assign-
ment Program (ASAP) [1] that is capable of making
preliminary assignments for the desired crosslinked
peptides based on mass. In Step 6, a mass list of all
possible crosslinked peptides obtained from ASAP is
used to automatically record tandem mass spectra of all
potential crosslinked precursor ion masses. We typi-
cally use the information dependent acquisition (IDA)
inclusion list feature of the QSTAR Analyst QS software
for this latter purpose. The MS/MS fragmentation data
are then analyzed to either accept or reject any pre-
dicted structure of a crosslinked peptide. As described
in the methods section, we have developed a program
called MS2Assign that automatically makes these prod-
uct ion assignments (Step 7). In the final Step 8, the
crosslinking information is used to derive a set of distance
constraints that is used together with structure modeling
algorithms to identify protein fold families [1].
To achieve the optimum experimental crosslinking
conditions for each protein target, it is best to analyze
the protein mixture directly after crosslinking [1, 8]. In
our protocol each crosslinked protein is checked ini-
tially by mass spectrometry directly following the
crosslinking reaction to determine the degree and qual-
ity of the crosslinks that are formed. A similar approach
has also been proposed by Pearson et al. [8]. To accom-
plish this goal, MALDI-MS were recorded for the vari-
ous proteins before and after each crosslinking reaction
condition and the shift in mass determined so as to be
consistent with no more than 1–3 modifications per
protein (data not shown). The number of crosslinks per
protein is monitored during the reaction so as to avoid
higher levels of crosslinking that could introduce geo-
metric distortion in the protein structure. In the case of
BS3 and similar analogs, a mass difference of 18 Da
exists between a crosslinker formed between two amino
acids (crosslink) versus one that is hydrolyzed at one
end (deadend modification). Therefore, the degree of
Figure 1. Flow chart summarizing the general strategy for pro-
tein crosslinking and fold-family recognition (MS3D) as originally
outlined by Young and colleagues [1]. The peptides labeled with
an asterisk are those that are crosslinked or modified.
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protein modification contributed by partially hydro-
lyzed crosslinkers can be assessed by mass spectro-
metry if sufficient resolving power is available. Based
on the determination of the number of crosslinks and
deadend modifications present in the crosslinked pro-
teins, the reaction conditions were separately optimized
to generate, on average, at least one crosslink for each
protein while minimizing the number of deadend mod-
ifications.
Chemical crosslinking of proteins generally results in
products that are more stable and more constrained
than the unmodified protein and therefore more likely
to be resistant to proteolysis. It is therefore critical that
conditions are used that insure the complete proteolysis
of all reaction products. A worse case scenario would be
the selective proteolysis of uncrosslinked proteins or
proteins that contain crosslinks close in sequence space
(less constriction) at the expense of crosslinked proteins
containing a significant conformational restriction (fur-
ther apart in sequence space). Moreover, the reaction of
lysines (in the case of amine-specific reagents such as
BS3) by the crosslinking reagent itself reduces the num-
ber of available basic proteolytic sites. When a variety of
denaturation strategies were examined in this study,
guanidine hydrochloride or acetonitrile were found to
yield the best peptide coverage after proteolysis (data
not shown). To assure optimal proteolysis, several
proteins were evaluated as substrates, including cyto-
chrome c and ribonuclease A. A panel of proteases were
used for proteolysis that included trypsin, Glu-C (or
V8), and chymotrypsin, either alone or in combination.
Before submitting digestion mixtures to LC-MS, a small
aliquot was analyzed using a fast screening process that
consisted of purification and fractionation of the sample
with Ziptips (C4-resin and/or C18-resin, step-wise elu-
tion) and analysis by MALDI-MS. In most cases, dena-
turation with acetonitrile was preferred as no extra salt
is introduced that could interfere with subsequent mass
spectrometry or chromatography experiments. As the
crosslinking reagents in this study were very hydropho-
bic, C-4 based nano-HPLC columns were preferred to
the more typical C-18 based columns as they tended to
elute these more hydrophobic peptides with better
efficiency.
Nomenclature for Peptide Crosslinks
If the crosslinking reaction is carried out at a low
crosslinker-to-protein ratio, the crosslinking reagent ei-
ther reacts at one or two independent amino acid side
chains of the protein (or the amino or carboxy terminus,
depending on the specificity of the reagents). After
proteolysis, these two outcomes can give rise to three
distinct peptide types; deadend modified peptides
(Type 0), internally crosslinked peptides (Type 1), or
crosslinking of two independent peptide chains (Type
2). To simplify the naming of these peptides, we pro-
pose a new nomenclature to distinguish and describe
these outcomes (see Figure 2). Such a uniform nomen-
clature has become necessary, as a variety of trivial
names have now been used to describe various types of
crosslinked peptides. For example, names such as
“deadend” [1], “decorated” [9], “end-capped” [8], or
“single chain with a derivatized lysine” [2] have been
used to describe a peptide modified at a single amino
acid.
In our proposed nomenclature, a Type 0 crosslinked
peptide would consist of a linear peptide that is singly
modified with the hydrolyzed and thus unreacted
crosslinking group at the other end. Such a peptide does
not provide any amino acid-to-amino acid distance
information, but can yield important information con-
cerning relative reactivities at various sites in a protein.
Furthermore, crosslinked peptides of Type 1 and Type
Figure 2. (a) Classification of crosslinked peptides into Type 0,
Type 1, and Type 2 outcomes. (b) One can also extend this
nomenclature to encompass combinations of these outcomes, such
as Type 0,1, Type 1,1, etc., for cases of multiple crosslinking
and/or modification events. In the latter cases, chain length or
mass (  ) and sequence position (N to C-terminus) determine
the order of the two numbers that designate the type of crosslink.
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2 are defined as resulting from reaction of the bifunc-
tional crosslinking reagent involving two separate
amino acids. After proteolysis, peptides are generated
that either lead to a linear peptide with two modified
residues (Type 1, intra-peptide or cyclic crosslink) or to
an inter-peptide crosslink connecting two peptide
chains (Type 2, two peptide chains). As shown in Figure
2a, the longer peptide chain of a Type 2 crosslinked
peptide is annotated as -chain whereas the shorter
peptide chain is marked as -chain. The use of an
,-nomenclature to differentiate the two peptides was
originally employed by Pearson and colleagues [8]. In
cases where both peptide chains contain the same
number of amino acids, the chain with the higher
molecular weight is called the -chain in contrast to the
lighter -chain. In the unlikely event that two peptides
have the same number of amino acids and the same
mass, the higher priority is given to the peptide whose
first amino acid (or second if the first two are the same,
etc.) has the larger mass. For completeness, there are
rare cases where two or more crosslinkers are present
on a peptide (or peptides) and one can extend this
nomenclature to include these outcomes as well. Sev-
eral of these latter outcomes are depicted in Figure 2b.
It should be pointed out that if a third peptide chain is
involved (see for example, Type 2,2), the smallest of the
chains should be designated as gamma ().
Nomenclature for MS/MS Product Ion Spectra
of Crosslinked Peptides
The nomenclature system for linear peptides of Roep-
storff and Fohlman [13], as subsequently modified by
Biemann [14] is now universally accepted. For peptides
with specific properties and features, however, it be-
came necessary to introduce specific nomenclature sys-
tems, such as that proposed by Ngoka and Gross for
cyclic peptides [19].
One of the major objectives of our study is to
construct a nomenclature to more accurately describe
the fragmentation processes of crosslinked peptides
under MS/MS conditions. In most existing automated
peptide fragmentation predictors, fragment ions for
linear peptides are considered to arise from cleavages at
the three positions of the repeating amide linkages,
C™CO (a,x-type) and CO™NH (b,y-type) and NH™C
(c,z-type). These cleavages are either heterolytic or
homolytic, and may also involve the transfer of one or
more hydrogens with charge retention at the N- (a,b,c-
type) or C-terminus (x,y,z-type). In addition to these
single backbone cleavages, multiple cleavages can occur
via charge-remote fragmentation processes to produce
internal peptide fragments or immonium ions (for re-
view, see [14]). Two of the most common ion fragments
seen under low-energy conditions are the y- and b-type
fragments (Scheme 1), and if two such cleavages of
these types occur in a peptide, internal acyl ion (also
called “internal b-type ion”), internal immonium ions
and amino acid immonium ions can result. It should be
noted that the structure of some bn ions (n  2–5) have
also been shown to have cyclic oxazolone structures [20,
21].
Over a decade ago, Hines et al. [22] wrote one of the
first algorithms for the interpretation of high-energy
CID spectra of peptides that incorporated this nomen-
clature. One of the key insights of this algorithm was to
recognize the mathematical relationship among peptide
ion types. For example, a peptide with an observable
protonated molecular ion of MH, a yn fragment (y-
center) would define a possible family of ions such as bm
 MH  1  yn, am  MH  1  yn-CO  MH  27 
yn, zn  yn  16 etc., where n  m  total number of
amino acids in the peptide. Since most current peptide
CID data are obtained under lower energy conditions,
fragmentation types are generally limited to the more
common ones, such as a, b, y, a-NH3, b-NH3, b-H2O,
and y-NH3 fragment ions.
Here, we propose a nomenclature for crosslinked
peptides that retains key features of the existing peptide
nomenclature but with modifications that more consis-
tently and accurately describe the fragmentation pro-
cess crosslinked peptides undergo. In the simplest ex-
ample, fragmentation of a Type 0 crosslinked peptide
(deadend crosslink) can be considered analogous to that
of a normal linear peptide containing an amino acid
that is modified. This is really no different than what
naturally modified peptides undergo through phos-
phorylation or glycosylation.
In the case where two side chains on a single peptide
are crosslinked, i.e., Type 1 or intra-peptide, interpreta-
tion and annotation becomes more complex. Such pep-
tides are similar to cyclic peptides or a combination of a
linear and cyclic peptide. In these cases, the nomencla-
ture proposed by Gross and colleagues [19] for cyclic
peptides is sufficient for their description. Although
this nomenclature was developed for cyclic peptides
where the absolute amino acid position is not known or
not relevant, an example was presented that is more
similar to the situation encountered in chemical
crosslinking, i.e., the oxytocin fragment, cy-
clo(YIQNA)PLG-NH2 where A is -amino suberic
acid, H2NCH[(CH2)5COOH]COOH. In Scheme 2, an
example is shown for the fragmentation of a Type 1
peptide involving a y,b-cleavage (e.g., y6b6) or alterna-
Scheme 1
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tively, the loss of an amino acid from the cyclic portion
of the crosslinked peptide (e.g., -AA4 or y3b3 cleavage
reaction).
The existing nomenclatures become insufficient,
however, with crosslinking involving two independent
peptide chains (Type 2, inter-peptide). An exception
would be the assignment of single or multiple cleavage
fragments that originate from cleavages in only one of
the two peptide chains. In these cases, they can be
treated in a manner analogous to that for a modified
linear peptide where one amino acid is “modified” by
the second peptide through the linker (see Scheme 3). In
this and other examples of the fragmentation of Type 2
peptides, we refer to the two peptides as - and
-chains (and when attached to their associated linker
segments as  and ), where the -chain is the longer
of the two peptides.
If cleavages occur at both peptide chains in a Type 2
crosslinked peptide, the situation becomes considerably
more complicated as can be seen in Scheme 4. For
example, if the cleavages involve both y-type reactions,
one forms a yy-type fragment. Alternatively, if the
reactions form b-type acylium ion fragments, then the
analogous fragment would be called a bb-type frag-
ment.
In the case where one has a mixed reaction involving
both y- and b-type fragmentation, one might observe
either yb- or by-fragments depending on which of
the two peptide chains each of the fragmentation pro-
cesses occurred (Scheme 5).
Up to this point, we have limited our treatment of
crosslinked peptide to the cleavage reactions and not
the products or their corresponding charge states per se.
In Scheme 6, structures for the singly charged two-
cleavage reactions products are proposed. In the case of
the bb-type fragment, one C-terminus is drawn as the
neutral ketene, which required the transfer of a proton
from the neighboring alpha-carbon. Other possibilities
could also exist to explain this latter ion-type.
In addition to singly charged ions, one also can also
generate doubly charged fragment ions. However, in
these cases, the resulting fragments must account for
both charges (see Scheme 7).
In addition to cleavages along the peptide backbone,
fragmentation within the linker arm structure itself may
occur. For example, for BS3 crosslinked linked peptides,
either of the two amide linkages are potential cleavage
sites, with the most likely cleavages being ones analo-
gous to the amides in peptides, i.e, y- and b-type
cleavages. In general, the amide linkages in BS3 are not
particularly labile and we have not observed them
fragmenting to any significant extent in this study.
However, other crosslinking reagents such as those
with ester, ether or disulfide linkages would be ex-
pected to be more labile and therefore undergo more
prominent fragmentation under CID conditions. For
these cases, we propose a nomenclature that considers
both the position of the bond scission (numbering from
the atom adjacent to the alpha-carbon of the crosslinked
amino acids) and the peptide that retains the charge.
Scheme 4
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Examples of such outcomes are shown in Scheme 8 for
a hypothetical linker containing additional sites of
cleavages where “L” represents the linker followed by
peptide charge retention ( or ) and the atom position
of the cleavage.
Examples of MS/MS Spectra from Crosslinked
Peptides
To examine tandem spectra of the various crosslinked
peptide types and to provide real examples of the
proposed nomenclature, a series of proteins were
crosslinked with BS3 and other amine-specific reagents.
Examples of tandem spectra are provided below for
Type 0, 1, and 2 crosslinked or modified peptides.
For a Type 0 peptide, a MS/MS spectrum is shown in
Figure 3 that was obtained from an HPLC separated
tryptic digest of cytochrome c crosslinked with BS3.
ASAP assigned the doubly charged parent ion for this
peptide at m/z 795.462 (M  1588.90 Da) as corre-
sponding to His(26)-Arg(38) containing a singly modi-
fied Lys-27. The resulting tandem spectrum of this
peptide contains an abundant series of b- and y-ions
which is a typical fragmentation pattern found in most
linear peptides. The position of the modified lysine is
further supported by the presence of the ion pairs y11
and y12 at m/z 1168.6 and 1452.8, and b1 and b2 at m/z
138.1 and 422.3, both of which show the expected
residue mass of 	M  284.1 Da. However, the immo-
nium ion for the BS3-modified lysine residue which
would be predicted to be present at m/z 257, NH2 
CH(CH2)4NHCO(CH2)6COOH, is not observed. Rather,
a strong signal at m/z 240.2 dominates this region and is
seen in this and other Type 0 peptides crosslinked with
Scheme 5
Scheme 6 Scheme 7
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BS3. The likely explanation for the m/z 240 ion is the loss
of ammonia from the expected BS3-modified immo-
nium ion at m/z 257, analogous to the loss of ammonia
seen in the immonium ions for lysine (m/z 101 3 84)
and N-acetyl--lysine (m/z 143 3 126) as originally
described by Falick et al. [23]. A mechanism for such a
loss is proposed in Scheme 9.
There are several lines of evidence that support the
identity of this m/z 240 ion. (1) Similar Type 0 peptides
formed with homologs of BS3 containing different
spacer arms (data not shown) show a similar dominant
ion in the low mass region at a mass consistent with the
number of methylenes, e.g., m/z 268 and 296 for
crosslinkers containing 8 and 10 methylenes, respec-
tively. (2) When Type 0 peptides originating from
proteins grown on N-15 media are subjected to MS/MS,
the immonium ion for the modified lysine shifts to m/z
241 (one N-15), consistent with the loss of ammonia. (3)
Such a modified lysine immonium ion, as will be shown
later, is not present in tandem spectra of Type 1 and 2
crosslinked peptides. (4) As mentioned above, N-acetyl-
-lysine has been reported to lose 17 Da (m/z 1433 126)
[23] and more recently, the m/z 126 ion was shown to be
considerably more abundant than its immonium ion
precursor [24]. We would expect that the additional
electron-donating alkyl substituent (R) would further
stabilize the m/z 240 product compared to N-acetyl--
lysine. Therefore, given that the m/z 240 ion does not
appear to have any overlap with other immonium or
dipeptide acylium ions, we propose that this unique
immonium-derived ion for modified lysines be used as
a “reporter ion” for crosslinked peptides of Type 0.
ESI-MS/MS spectra of crosslinked peptides of Type
1 (intra-peptide or cyclic crosslink) also contained a
fragmentation pattern indicative of its structural type.
Peptides containing a “cyclic” crosslink spanning across
a short distance of a few amino acids or less yielded
tandem mass spectra that were very similar to MS/MS
spectra of typical linear peptides. For example, the
doubly charged ion [M  2H]2 at m/z 587.342 corre-
sponding to a peptide assigned by ASAP as
M80IFAGIKKK88 from BS3-crosslinked cytochrome c
was subjected to collisional activation. The resulting
MS/MS spectrum shown in Figure 4a is consistent with
this peptide containing an internal crosslink between
two of the three adjacent N-terminal lysine residues. An
extensive b- and y-ion series provided the information
to position the crosslink between Lys-86 and Lys-87. In
contrast, the MS/MS spectrum of another Type 1
crosslinked peptide from cytrochrome c, Lys(39)-
Lys(55) (see Figure 4b) provided very few sequence
ions. The few fragment ions that were observed were
mostly low mass internal b-type ions with a few y-ions
from the C-terminal region of the peptide, i.e, y1 and y2
ions at m/z 147.1 and 261.2, respectively. The absence of
higher y- or b-type sequence ions appeared to be due to
the much longer lysine-to-lysine spanning distance of
this crosslink, i.e., Lys-39 to Lys-53. Indeed, this trend
has been observed in other Type 1 peptides containing
Scheme 8
Figure 3. ESI-MS/MS spectrum of a Type 0 (deadend) modified
peptide obtained from cytochrome c, His(26)-Arg(38) modified
with BS3 at residue Lys-27. The [M  2H]2 at m/z 795.462 (M 
1588.90) was selected for CID. A collision energy of 47 eV was
used to acquire this spectrum. Scheme 9
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a long internal crosslink (cyclic structure) with a short
linear sequence. The low abundance or absence of
fragments from the “cyclic” components of Type 1
peptides is not unexpected since two separate cleavages
are required to yield such an observable fragment
which would typically require more energy than a
single cleavage reaction. Given that these latter type of
crosslinked peptides are more likely to define an im-
portant (long) distance constraint, the pattern seen for
Type 1 peptides with long internal crosslinks might be
useful for initial screening purposes.
Fragmentation mechanisms of crosslinked peptide of
Type 2 are potentially the most challenging to interpret.
This task is further complicated by the lack of any
bioinformatics tools that could account for their frag-
mentation in a rigorous and throrough manner. For
example, the ESI-MS/MS spectrum of an inter-peptide
crosslinked peptide from cytochrome c is shown in
Figure 5 that can be assigned to two peptides;
H26KTGPNLHGLFGR38 and G6KK8. The only amines in
these two sequences that would have been available for
crosslinking in the intact protein are Lys-27 and Lys-7.
Single cleavage products are present in this spectrum
that can be assigned as originating from one or the other
of the two peptide chains, primarily y-type ions. The
fragment ions corresponding to these two peptides are
therefore designated with either the  or  subscript to
indicate the peptide of origin. As this particular
crosslinked peptide contains two different amino acids
at the C-termini, Arg-38 and Lys-8, two y1-ions are
present at m/z 175.1 (y1) and 147.1 (y1). A more
extensive set of y-ions are also observed for the -chain
that cover all but the y4 and y8 ions. Although the
spectrum was closely examined for the possible pres-
ence of fragment ions originating from cleavages in-
volving both peptide chains (e.g., yy, yb, bb, etc.),
no such ions were observed.
Several other examples of Type 2 peptides were also
subjected to MS/MS analysis. In one case, the tandem
mass spectrum of the ribonuclease A crosslinked pep-
tides K1ETAAAK7 (-chain) and N34LTKDR39 (-chain),
generated a pattern similar to the previous example and
consisted of a dominant y-series ions (note: under-
scored residues imply crosslinking sites). The MS/MS
spectrum of the triply charged ion [M  3H]3 at m/z
534.643 revealed a nearly complete y-ion series for
both peptide chains; y1–6 at m/z 147.1, 218.2, 289.2,
360.3, 461.3, and 590.3 (-chain), and y1–4 at m/z at
175.1, 290.2, 637.42, and 688.02 (-chain). The mass
difference between the y2 and y3 ions clearly showed
the position of crosslink in the -chain as Lys-37. With
the exception of a relatively weak ions at m/z 785.5 and
393.32 (singly and doubly charged ions for b1y4,
K1–T36KDR39), there were no significant fragments in
this MS/MS spectrum that involved both peptides. In
another example, a crosslinked peptide from myoglo-
bin, R139NDIAAKY–K147ELGFQG153, a dominant bn-ion
series was observed in the MS/MS spectrum for the
first six amino acids of the -chain after selection of the
[M  3H]3 precursor ion at m/z 622.73. However,
close inspection also revealed the presence of three ions
that originate from cleavage reactions involving both
peptide chains, i.e., m/z 639.42 (b7b2; RNDIAAK–
KEL), and m/z 582.82 and 1164.6 (b7b2; RNDIAAK–
Figure 4. ESI-MS/MS spectra of Type 1 crosslinked peptides
obtained from cytochrome c. (a) peptide M80-K88 with parent ion
[M  2H]2 at m/z 587.342 (M  1172.66) and crosslink between
Lys-86 and Lys-87, and (b) peptide Lys(39)-Lys(55) with parent
ion [M  3H]3 at m/z 655.703 (M  1964.08) and crosslink
between Lys-39 and Lys-53. The crosslinked peptides are classi-
fied as Type 1 and contain a cyclic, intra-peptide crosslink.
Collision energies were 32 eV and 36 eV, respectively.
Figure 5. ESI-MS/MS spectrum of Type 2 crosslinked peptide
obtained from cytochrome c consisting of -chain, His(26)-
Arg(38), and -chain, Gly(6)-Lys(8), crosslinked between Lys-2
and Lys-7. The [M  4H]4 peak at m/z 476.514 (M  1902.09)
was selected as the precursor ion with a collision energy of 24 eV.
The crosslinked peptide contains an inter-peptide crosslink be-
tween 2 peptide chains (Type 2).
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KE). In this and the preceeding example, the ions
resulting from two peptide chain cleavages (by-
and/or bb-ions, in these cases) were relatively weak.
On average, these fragments were10% as abundant as
the the dominant y and b-ion series involving only one
or other of the two peptide chains.
In a separate study to investigate the kinetics of BS3
crosslinking using the model pentapeptide, RKDVY
(thymopentin), several MS/MS spectra were obtained
from the reaction products. Although the predicted
Type 2 crosslinked product(s) of this reaction is com-
plicated by the presence of four reactive amines (2
N-terminal amines and 2 lysines) which can yield three
possible products, the MS/MS spectrum of the triply
charged precursor ion [M  3H]3 at m/z 499.973
yielded some interesting results (Figure 6). In addition
to a short y- and b-ion series, several bb-type double
cleavage ions were detected in their doubly charged




2 (b3b2). The di-acylium ion struc-
ture of these bb-type ions appear to be preferentially
formed in preference to their singly charged ion coun-
terparts (see Schemes 6 and 7). But again, these ions
were typically less abundant than the single chain
cleavage products.
MS2Assign for Automated Assignment of MS/MS
Spectra
In the previous section, interpretation of several
crosslinked peptides of Type 0, 1, and 2 were presented
based on manual interpretation and considering single
or multiple cleavage reactions. These interpretations
were relatively straightforward for Type 0 crosslinked
peptides, but quickly became problematic for peptides
of Type 1 and 2 where the products were (partially)
cyclized (Type 1) or contained two peptide chains (Type
2). As no computer program was available to interpret
and analyze tandem mass spectra of crosslinked pep-
tides of these types, we developed the program
MS2Assign. MS2Assign is designed to compare exper-
imentally observed fragment ion masses with a theoret-
ical mass list generated by an in silico fragmentation of
a proposed crosslinked peptide or pair of peptides. This
program was then used to evaluate the MS/MS spectra
obtained for modified and crosslinked peptides pre-
sented in the previous section. For our purpose, an
arbitrary abundance threshold was chosen (typically
2–5% of base peak) to define the most abundant product
ions and the masses of these ions were submitted to
MS2Assign for analysis. For simplicity, and to limit the
combinatorial explosion of possible assigments that
MS2Assign could make, we further limited the types of
cleavages to the more prominant a-, b-, and y-type ions
as well as internal ymbn acyl ions. The program then
generates a file showing the assignment of these masses
to specific peptide fragment and their structures, the
nomenclature for that particular ion type, and the
calculated mass accuracy between observed and theo-
retical ions. On average, 91% of the observed frag-
ment-ions for any given crosslinked peptide containing
one crosslink or deadend modification of Type 0, 1, and
2 were matched with an in silico fragment by
MS2Assign (see Table 1). Therefore, MS2Assign ap-
pears to be capable of making both accurate and com-
plete assignments for the vast majority of products ions
observed from all three types of crosslinked peptides.
To examine more fully the capabilities and limita-
tions of MS2Assign, we also investigated some
crosslinked peptides containing more than one
crosslinker modification. Figure 7 shows a tandem mass
spectrum of the N-terminal peptide M1KKIAIIPAR10
obtained from cytidine 5-monophosphate N-acetyl-
neuraminic acid synthetase that contains two crosslink-
ing modifications as originally assigned by ASAP. Ac-
cording to our nomenclature, this peptide is classified
as Type 0,1, since it is a single peptide containing one
dead-end crosslink on Lys-3 (Type 0) and one intra-
peptide or cyclic crosslink between the N-terminal
Met-1 and Lys-2 (Type 1). In this case, the peptide
structure was confirmed by tandem mass spectrometry
as evident from the number of y- and b-type ions that
could be assigned by MS2Assign, i.e., 16 out of 20 of the
most abundant fragment could be assigned. Specifi-
cally, the abundant b3-ion at m/z 682.4 indicates that the
crosslinking reagents reacted with residues Met-1,
Lys-2, and Lys-3, all located at the N-terminal end of the
peptide. As discussed previously, the abundant re-
porter ion at m/z 240.2 suggests that the Type 0 crosslink
has formed with a lysine residue rather than with the
Figure 6. ESI-MS/MS spectrum of a Type 2 crosslinked peptide
dimer obtained from crosslinking two chains of the pentapeptide
thymopentin, RKDVY, with the crosslinking reagent BS3. The
triply charged precursor ion [M 3H]3 at 499.973 (M 1496.89)
was fragmented using a collision energy of 26 eV to yield several
double cleavage ions of the bb type that were detected as doubly
charged fragment ions. Two insets show such double cleavage
ions in detail, i.e., the doubly charged ion b3b3 at m/z 469.3
2 and
doubly charged ion b4b3 at m/z 518.8
2. Although only one of
the three possible crosslinked products is shown above, it is likely
that the other two possible crosslinked peptides are also present in
this mixture (i.e., involving the two free N-termini or the N-
terminus and Lys-2) since the observed product ions masses are
consistent with all three isomers.
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-amino group of the N-terminal methionine. Finally,
the observed b2/a2-ion pair at m/z 398.2 and 370.3
provides evidence that the cyclic Type 1 crosslink
connects Met-1 (through the -amino group) and Lys-2.
A second example of a multiply modified peptide was
encountered from cytochrome c carrying two deadend-
type modifications (Type 0,0). In this latter case, the
precursor ion at m/z 493.312 for the peptide K87KGER91
was selected for CID and MS2Assign identified 10 out
of the 11 most abundant fragment ions, confirming that
the two N-terminal lysines were modified (data not
shown).
MS2Assign can also discriminate between several
alternative structures. For example, the peptide
K39TGQAPGFSYTDANKNK55 with a single deadend
modified lysine (Type 0) was presented by ASAP as
best matching the experimental mass of 1981.90 Da for
the tryptic peptide derived from crosslinked cyto-
chrome c. The tandem mass spectrum of this peptide
was recorded for the triply charged precursor ion at m/z
661.643 (M  1981.90) and the product ion mass list
was submitted to MS2Assign in two separate ways; the
deadend modification was either assigned to Lys-53 or
Lys-39. When the modification was assigned to Lys-53,
MS2Assign matched 28 of the 30 submitted fragment
ions (93%) whereas when matched to Lys-39, only 17
fragment ions (57%) could be assigned. It should be
pointed out that none of the 17 product ions that could
be assigned to the Lys-39 modified peptide were unique
and all of these ions could also be assigned to the Lys-53
modified peptide. In addition, no cleavages were ob-
served between the crosslinker and lysine residue, a
process that is rarely observed. (MS2Assign is capable
of both considering or not considering the fragmenta-
tion of lysine and crosslinker through an on/off switch
in the program’s input options.) Close scrutiny of this
tandem spectrum reveals why MS2Assign made a bet-
ter assignment for a Lys-53 deadend modification; an
y4-y7-ion series containing a modified lysine is observed
at m/z 659.4, 730.4, 845.5, and 946.5 while the b7-b9-ion
series at m/z 640.4, 787.4, and 874.5 did not show a
modified lysine. A similar example was encountered for
the Type 0 modified peptide, T34GHPETLEKFDKF46,
obtained after chymotryptic proteolysis of myoglobin
crosslinked with BS3. The triply charged precursor ion
for this peptides (m/z 568.943) was subjected to CID
and two key fragments were observed that could be
used to distinguish these two sites, i.e., the y2- and
y3-ions (m/z 294.2 and m/z 409.2) did not bear any
evidence of a modified lysine and therefore favored
Lys-42 as the site of modification. Overall, MS2Assign
assigned 93% of the fragment ions for the peptide
containing a Lys-42 modification (25 of 27 ions
matched) compared to 85% for the alternative structure
crosslinked at Lys-45 (23 of 27 ions matched).
Table 1. Automatic assignment of MS/MS crosslinked peptide spectra using MS2Assign
Crosslink type Precursor ion Predicted sequence (ASAP) MS/MS-ions matcheda Ions matched (%)a
2 661.683 S47YTDANKNK–K39TGQAPGF 16/17 94
2 476.514 H26KTGPNLHGLFGR–G6KK 26/26 100
2 534.643 K1ETAAAK–N34LTKDR 33/39 85
2 622.663 R139NDIAAKY–K147ELGFQG 22/38 79
2 499.973 R1KDVY–R1KDVY 30/38 79
1 781.343 E86TGSSKYPNCAYKTTQANK 18/22 82
1 655.703 K39TGQAPGFSYTDANKNK 24/24 100
1 587.343 M80IFAGIKKK 23/24 96
0 530.963 G89EREDLIAYLKK 16/17 94
0 795.462 H26KTGPNLHGLFGR 17/17 100
0 661.643 K38TGQAPGFSYTDANKNK 28/30 93
0 568.943 T34GHPETLEKFDKF 25/27 93
0,1b 717.943 M1KKIAIIPAR 16/20 80
0,0b 493.312 K87KGERc 10/11 91
aMatching of most abundant fragment ions (i.e., abundance  2–5% of base peak) against MS2Assign ‘in silico’ fragmentation. The reacted lysine
or N-terminal amino acid residues are underlined.
bA peptide with two crosslinking events, i.e., deadend (Type 0) and internal (Type 1).
cThe BS3-like crosslinking reagent homolog, bis(sulfosuccinimidyl)decanoate, was used in this experiment.
Figure 7. ESI-MS/MS spectrum of Type 0,1 crosslinked peptide
showing two crosslinking events, one deadend crosslink on resi-
due Lys(3) (Type 0) and one intra-peptide/cyclic crosslink be-
tween N-terminal residue Met-1 and Lys-2 (Type 1). The doubly
charged precursor ion, [M  2H]2 at m/z 717.942 (M  1433.86),
was selected for CID with a collision energy of 40 eV. The peptide
M1KKIAIIPAR10 was obtained from CMP-NeuAc synthetase.
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MS2Assign can also be used to assign fragments in
MALDI-PSD spectra. In our previous report [1],
MALDI-PSD spectra of crosslinked peptides were often
found to reveal abundant fragment ions directly at the
site (or sites) of the crosslinker modification. Figure 8a
shows a MALDI-PSD spectrum of the Type 1 crosslink
tryptic peptide from cytrochrome c,
G23GKHKTGPNLHGLFGR38, which was internally
crosslinked between Lys-25 and Lys-27. The most
prominent fragment-ion other than immonium ions is
the b5/a5-ion pair at m/z 647.0 and 619.0. The b5-
fragment ion was derived from a cleavage of the
peptide backbone amide bond between crosslinked
residue Lys-27 and the adjacent amino acid Thr-28. In
addition, other abundant b-type ions (e.g., b6 and b9–12)
encompassing the crosslinking site were present. Under
ESI-MS/MS conditions on a QSTAR, very different
products ions were observed. For example, the charac-
teristic b5-ion at the crosslinking site (m/z 323.7
2)
appeared much weaker in the ESI-MS/MS spectrum
(see Figure 8b) compared to the PSD spectrum. Instead,
a complete y3- through y11-ion-series was observed.
Distance Constraints
In terms of providing distance constraints, Type 2
crosslinked peptides are ususally considered the most
valuable [1]. However, it should also be pointed out
that intra-peptide crosslinks of Type 1 can be of equal
value if the two amino acids involved in the crosslink
span a significant number of amino acids. Crosslinked
peptides of Type 1 and 2 qualify as a distance constraint
only when the distance between connected lysine (or
other amino acids) pairs exceeds the maximum span-
ning distance that a crosslinker could reach in the most
extended beta-strand protein conformation [25]. The
minimum number of consecutive amino acids between
reactive lysines to provide useful distance constraints is
therefore a function of the length of the spacer arm. In
the case of BS3-type crosslinkers, this distance is chem-
ically defined as -CO™(CH2)6™CO-. Assuming a distance
of 3.5 Å between the C’s of neighboring amino acids in
their most extended  strand conformation, a
crosslinker such as BS3 requires a minimum of six
amino acids between the Lys-Lys pair to generate a
useful distance constraint. In this case the maximum
spanning distance of the BS3 crosslinker (23.8 Å) is
smaller than the actual Lys(C)-Lys(C) distance given
by the primary sequence (24.5 Å  7  3.5 Å). Table 1
shows some examples of different Type 1 crosslinked
peptides such as crosslinked peptides
E86TGSSKYPNCAYKTTQANK104 (crosslink between
Lys-91 and Lys-98, from RNase) and
K39TGQAPGFSYTDANKNK55 (crosslink between
Lys-39 and Lys-53, from cytochrome c). In these latter
two examples, 6 and 13 amino acids separate the
BS3-crosslinked lysine residues, respectively, and there-
fore qualify as distance constraints. The Type 1
crosslinked peptide M80IFAGIKKK88 (crosslink be-
tween Lys-86 and Lys-87, from cytochrome c) on the
other hand, only provides redundant information.
As mentioned previously, the choices of proteases
employed to digest the crosslinked proteins are impor-
tant to the identification process. In the spectrum shown
in Figure 9, a peptide isolated from crosslinked cyto-
chrome c after trypsin digestion yielded the Type 1
peptide K39TGQAPGFSYTDANKNK55 (see Figure 9a)
Figure 8. Fragmentation of the Type 1 peptide from cytochrome
c, G23GKHKTGPNLHGLFGR38, crosslinked between Lys-25 and
Lys-27: (a) MALDI-PSD spectrum selecting the singly charged [M
 H] at m/z 1814.0. (b) ESI-MS/MS spectrum acquired on the
QSTAR after selecting the quadruply charged [M  4H]4 at m/z
454.244 using a collision energy of 22 eV. Figure 9. ESI-MS/MS spectra of two crosslinked peptides en-
compassing the same sequence, Lys-39 and Lys-53, from cyto-
chrome c. (a) Type 1 peptide K39TGQAPGFSYTDANKNK55 with
crosslink between Lys-39 and Lys-53 with precusror ion [M 
3H]3 at m/z 655.703 and (b) same peptide digested with chymo-
trypsin to yield the Type 2 peptide with -chain Ser(47)-Lys(55)
and -chain Lys(39)-Phe(46) with precursor ion [M 3H]3 at m/z
661.643. A collision energy of 36 eV was used for both precursor
ions.
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containing an internal crosslink between residues
Lys-39 and Lys-53. But when both tryptic and chymot-
ryptic digestion was employed, a Type 2 peptide re-
sulted that encompassed the same amino acids (see
Figure 9b). This latter peptide originated from the
tryptic peptide with a cleavage at Phe-46, yielding a
peptide -chain (residues 47–55) and -chain (residues
39–46). In this case, both the Type 1 or Type 2
crosslinked peptides contain the same distance con-
straint and can be considered equally valuable. Inter-
estingly, the MS/MS spectra for these two peptides
showed very different product ions that were consistent
with early observations regarding the fragmentation of
Type 1 and 2 peptides. For example, while the MS/MS
spectrum of the Type 1 peptide produces relatively low
mass internal b-type ions, the Type 2 crosslinked pep-
tide reveals an extensive series of y- and b-type se-
quence ions. Moreover, the characteristic y-ion series of
the resulting peptide -chain (K39TGQAPGF) at m/z
166.1(y1), 223.1(y2), 320.2(y3), and 391.3(y4) defines
the chymotrypsin site as Phe-46 and not Tyr-48, the
other likely cleavage site.
Conclusions
Previously, we reported a proof-of-principle applica-
tion to identify protein fold families that combined
intramolecular crosslinking, mass spectrometry and se-
quence threading (MS3D) [1]. In the current study, we
developed a general nomenclature for assigning
crosslinked peptides as Type 0, 1, and 2, depending on
the chemical nature of the crosslinking and how many
peptide chains are present. Moreover, a detailed inves-
tigation into how crosslinked peptides fragment by CID
led to the development of a program, MS2Assign,
which can assign these product ions in a systematic and
thorough fashion.
Briefly, tandem mass spectra of crosslinked peptides
were found to display some very unique features that
were useful in their interpretation. Crosslinked pep-
tides of Type 0 were found to generate very abundant
and characteristic reporter ions that arise through loss
of ammonia from lysine-modified immonium ion at m/z
240.16. The same ion was not observed for Type 1 and
2 crosslinked peptides in these studies. On the other
hand, Type 1 peptides that contain an internal crosslink
on a single peptide chain show dominant fragment ions
for the linear (non-cyclic) region only, often resulting in
a spectrum depleted of the typical y- and b-type se-
quence ions. Type 2 peptides generated extensive y-
and b-type fragments as one might expect for two
independent peptide chains, each containing a modi-
fied amino acid. Product ions that were generated by
cleavage of both peptide chains were present but of low
abundance, typically less than 10% of the ion abun-
dances associated with cleavages exclusive on one or
the other of the peptide chains. The abundances of these
latter product ions would likely be improved if higher
collision energies were chosen, something that was not
attempted in this current study. Nonetheless, these low
abundance two-chain cleavage products, i.e., yy,
yb, by, or bb, should not be ignored as they can be
used to distinguish between specific sites of crosslink-
ing should any ambiguity exist.
Ideally, it would be better to consider alternative
possibilities in the spectral assignments carried out by
MS2Assign in addition to the crosslinked peptide in
question, including unmodified peptides of the same
mass. Such an approach would provide appropriate
negative controls and limit the possibility of false-
positives, thereby providing statistical and probabilistic
rigor to the MS3D strategy. In conventional proteomics,
scores are routinely provided in the spectral matches
for this purpose, e.g., Sequest (Xcorr) [26] and Sonar
(expectation values) [27]. However, given the relatively
small number of crosslinked peptide spectra currently
in our database, it will likely take some time before
sufficient data is available to warrant an analogous
approach here.
In conclusion, we have shown that experimental and
computational/bioinformatics tools are now available
to begin to tackle interesting biological systems. This
current work describes bioinformatics tools to automat-
ically process tandem mass spectra and to support the
structure of crosslinked peptides. Together with the
program ASAP, the necessary programs are now avail-
able to rapidly process both MS data (ASAP) and
MS/MS data (MS2Assign) in a high-throughput fash-
ion. Both ASAP and MS2Assign are currently available
as Web server versions and can be freely accessed by
other scientists. Further studies in our laboratories are
being carried out to further improve the MS3D strategy,
including the synthesis and use of novel crosslinking
reagents, experiments to better understand the kinetics
of the crosslinking reactions, and the use of protein
mixtures that contain both normal and 15N-isotopically
labeled proteins. With these and other tools, one can
envision obtaining sets of distance constraints from
various proteins, whether they generated from intra-
protein reactions or between proteins in a larger com-
plex, in a more rigorous and efficient manner.
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